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Abstract
—Trivalent arsenic [As(III)] is a well-known environmental toxicant that causes a wide range of
organ-specific diseases and cancers. In the human liver, As(III) promotes vascular remodeling, portal
fibrosis, and hypertension, but the pathogenesis of these As(III)-induced vascular changes is
unknown. To investigate the hypothesis that As(III) targets the hepatic endothelium to initiate
pathogenic change, mice were exposed to 0 or 250 parts per billion (ppb) of As(III) in their drinking
water for 5 weeks. Arsenic(III) exposure did not affect the overall health of the animals, the general
structure of the liver, or hepatocyte morphology. There was no change in the total tissue arsenic
levels, indicating that arsenic does not accumulate in the liver at this level of exposure. However,
there was significant vascular remodeling with increased sinusoidal endothelial cell (SEC)
capillarization, vascularization of the peribiliary vascular plexus (PBVP), and constriction of hepatic
arterioles in As(III)-exposed mice. In addition to ultrastructural demonstration of SEC defenestration
and capillarization, quantitative immunofluorescence analysis revealed increased sinusoidal
PECAM-1 and laminin-1 protein expression, suggesting gain of adherens junctions and a basement
membrane. Conversion of SECs to a capillarized, dedifferentiated endothelium was confirmed at the
cellular level with demonstration of increased caveolin-1 expression and SEC caveolae, as well as
increased membrane-bound Rac1-GTPase.
Conclusion— These data demonstrate that exposure to As(III) causes functional changes in SEC
signaling for sinusoidal capillarization that may be initial events in pathogenic changes in the liver.
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The vascular effects of arsenic are a global public health concern that contribute to disease in
tens of millions of people worldwide.1 Whereas the role of environmental contaminants in the
etiology of vascular diseases and in the vascular contributions to organ dysfunction remains
poorly defined, epidemiological studies have associated As(III) exposures to increased risk of
cardiovascular diseases1 and vascular contributions to liver disease.2 Liver effects associated
with arsenic in drinking water include noncirrhotic portal fibrosis and, to a lesser extent, portal
hypertension.2,3 These pathologic conditions involve increased vascular channels in the portal
regions of the liver. Higher levels of chronic As(III) consumption increase urinary levels of
porphyrins, a biomarker for liver injury, which are more pronounced in people under 20 years
of age.4 In addition, cardiac and liver disorders are the major side effects of therapeutic As(III)
regimes that treat leukemias.5 Despite epidemiological evidence that the liver vasculature is a
pathogenic target of chronic As(III) ingestion,2 the direct effects of As(III) on liver vascular
cells are unknown.
In other vascular beds and isolated cell cultures, As(III) affects both endothelial and smooth
muscle cell physiology. Arsenic(III) stimulates angiogenic processes in cultured endothelial
cells and neovascularization in intact mouse and avian models.6–9 These angiogenic effects
promote tumorigenesis in mice, as well as vascular remodeling.10,11 Stimulation of
endothelial cell proliferation occurs at concentrations of As(III) that are not cytotoxic, whereas
higher concentrations are cytotoxic and inhibit angiogenesis in tumors.10,11 Arsenic(III)
stimulates cultured smooth muscle cells to proliferate and express vascular endothelial cell
growth factor (VEGF), a primary mediator of angiogenesis.12 Although these effects of As
(III) on cells from systemic blood vessels are well recognized, there is little data on the effects
of As(III) exposures on liver vascular remodeling or specifically on the fenestrated sinusoidal
endothelium.
The liver sinusoidal endothelial cells (SECs) are highly specialized fenestrated cells that are
unique in the extensive heterogeneity of vascular endothelium.13 Early in development, these
cells differentiate to lose markers of a continuous endothelium, such as junctional expression
of platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) and a basement membrane
containing the matrix protein laminin-1.14 In the differentiation process, the SECs become
fenestrated to allow sieving of circulating nutrients, lipids, and lipoproteins for normal liver
metabolism.13 The SEC angiogenic process is different from angiogenesis in endothelial cells
of systemic vessels, because there is no increase in sinusoidal vessel number or density. Instead,
SEC angiogenesis is a dedifferentiation and maturation process called capillarization with
diagnostic hallmarks of SEC defenestration and renewed surface expression of PECAM-1 and
laminin-1 proteins.13,15–18 SEC defenestration and formation of tight intercellular junctions
limits transendothelial cell transport.13,16,19,20 Capillarization precedes vascular remodeling
of other liver vessels, such as hepatic arterioles and PBVP, causing blood flow shunting,
vascular channel formation, and eventually liver fibrosis.15,16,21 Liver angiogenesis in
general is recognized as an important pathogenic process not only in portal fibrosis, but also
in portal hypertension and progression of HCCs.18,22–25 Finally, animal models have been
used to demonstrate that liver capillarization affects the systemic vasculature by decreasing
liver metabolism of lipids, lipoproteins, and glucose to promote atherogenesis in response to
environmental stresses and aging.13,26,27
In mouse tumors or surrogate in vivo neovascularization assays, low to moderate levels of As
(III) (5–250 ppb) in drinking water are angiogenic.7,28 However, As(III) effects on the liver
endothelium or pathogenic angiogenic processes in the liver are unknown. The aim of this
study was to investigate whether a chronic, human-relevant, environmental exposure to As(III)
causes SEC dedifferentiation and dysfunctional capillarization in intact mice. The data indicate
that prolonged As(III) exposure causes SEC maturation and sustained functional changes in
SEC cell signaling.
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Animal exposures were performed in agreement with institutional guidelines for animal safety
and welfare at Dartmouth College and the University of Pittsburgh. C57BL/6N male mice,
ages 6–8 weeks weighing approximately 20 g were obtained from Taconic Farms (Hudson,
NY) or the National Cancer Institute. Standard mouse chow and drinking water solutions were
fed ad libitum for 5 weeks to mice housed in boxes of 3. Fresh drinking water solutions
containing 250 ppb sodium arsenite (Fisher Scientific, Pittsburgh, PA) were prepared triweekly
using commercially bottled drinking water (Giant Eagle Spring Water, Pittsburgh, PA).
Measurement of Tissue Total Arsenic Levels
Total liver arsenic was measured by hydride generation with atomic fluorescence detection
following tissue digestion in phosphoric acid, as described.29 The limit of detection for
inorganic arsenic by this analysis was 15 pg.
Scanning and Transmission Electron Microscopy
Tissues were prepared for SEM and TEM as described.30
Morphometric Quantitation of Fenestrae
SEM images from 3 control mice or 3 arsenic-exposed mice were captured. Hepatic zones 1
and 3 were identified based on extracellular matrix (ECM) deposition around the large vessels
and visualization of bile ducts. Vessels having excess ECM were considered portal veins (zone
1) and large vessels with little or no ECM were considered central veins (zone 3). Once zones
were identified, images from representative regions of 5 sinusoids in each zone were taken at
approximately 100 μm from the respective large vessel. Porosity (open area of the sinusoid
wall) was calculated using MetaMorph software (Universal Imaging Corp., Downingtown,
PA). The total area within a representative region of sinusoid was determined in square
micrometers. Within this area, the total open area was quantified. Open areas of fenestrae were
summed, divided by the total area, and multiplied by 100 to give the percent porosity. The
porosities of the 5 sinusoids in each zone were averaged to give a single value (n) per mouse.
Immunofluorescence Microscopy
After 5 weeks of exposure, 5 mice per group were killed with CO2. Livers were excised, snap
frozen in liquid nitrogen, and stored at −80°C until sectioning. Cryostat sections (8 μm) on
charged glass slides were fixed for 1 minute in cold methanol. Sections were stained as
described30 using antibodies described in Table 1 and coverslipped using Fluoromount G
(Southern Biotech, Birmingham, AL). Fluorescent images were captured with an Olympus
Fluoview 500 confocal microscope (Malvern, NY) or a Nikon microphot-FXL microscope,
fitted with an Olympus CCD digital camera.
Quantitative Immunofluorescence of Sinusoidal Protein Levels
Five random 400× confocal midlobular images of immunofluorescence signals in liver sections
were captured using identical exposure times. Using MetaMorph software, images were color
separated, changed to monochrome format, and the threshold pixel values were set to equal
levels. Pixel number per 400× field was quantified and the average percentage of positively
fluorescent pixels per field in the 5 fields was calculated to give a single value per mouse.
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Morphometric Analysis of PBVP
Tissue slices were costained for PECAM-1 and α-SMC actin. Hepatic arteries stained positive
for both PECAM-1 and α-SMC actin, veins were predominantly PECAM-1 positive with a
slight amount of α-SMC actin, and lymphatic vessels stained slightly for PECAM-1 with no
α-SMC actin. Epi-fluorescent images of 2 portal tracts per section of normal or As(III)-exposed
livers were captured and exported to MetaMorph. Luminal area of hepatic arteries, as well as
wall thickness were captured and compared. Vascularization of the PBVP was measured as
the number of PECAM-positive or PECAM/α-SMC actin–positive luminal structures per duct
wall.
In Situ Isolation of SEC Membrane Proteins with Colloidal Silica
The luminal SEC membranes of control or As(III)-exposed mice livers were isolated by in
situ membrane density perturbation technique as described.31 The proteins in the respective
membrane fractions were separated by SDS-PAGE and probed by Western analysis with
antibodies described in Table 1.
Statistical Analysis
The values for the control and As(III)-exposed mice were analyzed for statistical differences
by unpaired t test or 2-way ANOVA using Prizm 4.0 software (GraphPad, San Diego, CA).
Results
Arsenic Does Not Accumulate in the Liver
After 5 weeks of exposure, there were no obvious health differences between the control mice
and mice that drank water containing 250 ppb arsenic. The total animal weights and liver/body
weight ratio did not vary (data not shown) suggesting that food and water intake was equal
between the groups and there was no hepatomegalia. There was also no increase in liver tissue
levels of total arsenic in the mice fed arsenic-containing water (control = 3.8 ± 1.3 ng/g tissue;
arsenic-exposed = 2.9 ± 1.4 ng/g tissue, n = 6). These data confirm earlier reports that arsenic
does not accumulate in mouse liver until drinking water levels exceed 1.0 ppm.32
Chronic Low Levels of As(III) Exposure Induced Sinusoidal Capillarization
The effects of As(III) exposure on the ultrastructure of the sinusoidal endothelium were
examined using both SEM and TEM. The SECs in normal mice contain numerous sieve plates
with open fenestrae (Fig. 1). The sinusoids in As(III)-exposed mice were observably
defenestrated and the endothelium was continuous, indicating capillarization (Fig. 1).
Quantitative morphometric analysis revealed that As(III) caused a 4-fold to 5-fold decrease in
porosity (i.e., open space per unit area; Fig. 1, graph) in either zone 1 or zone 3 of the sinusoids.
The surface of the As(III)-exposed sinusoids showed an increase in surface projections, some
of which were microvilli from the underlying hepatocytes protruding through the SEC fenestrae
(Fig. 1). The TEM images in Fig. 2 confirm that decreased sinusoidal porosity in As(III)-
exposed mice was paralleled by increased hepatocyte microvilli filling of the space of Disse.
Similar microvilli increases were attributed to a compensatory mechanism to recover lost
nutrient uptake.13,33 In contrast, mitochondria and other organellar structures within the
hepatocytes retained normal ultrastructure. The magnified images in Fig. 2B demonstrate As
(III)-stimulated loss of fenestrations and gain of a rudimentary basement membrane. Caveolae,
sparse in the SECs of control mice, were more evident in the capillarized SECs of the As(III)-
exposed mice.
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As(III) Induces Sinusoidal PECAM-1 and Lami-nin-1 Protein Expression
As discussed above, capillarized SECs express surface PECAM-1 and develop a laminin-1
containing basement membrane.13,15,34 Quantitative immunofluorescence measurements
were used to determine whether the As(III)-induced ultrastructural changes observed in Figs.
1 and 2 accompanied localized increased expression of these proteins. PECAM-1 expression
was selectively increased in sinusoids of As(III)-exposed mice, but not in the endothelium of
large vessels, such as the portal veins (Fig. 3A,B). The apparent increase in hepatic artery
PECAM-1 staining may have been caused by contraction of the vessel lumen (Fig. 4).
Midlobular laminin-1 expression also increased (Fig. 3A) and merging the red and green
channels in Fig. 3A revealed punctate laminin-1 staining (focal red staining) that is adjacent
to the sinusoidal PECAM-1. This may indicate that protein expression in stellate cells, which
are a primary source of laminin-1,16 was also stimulated by As(III). The stellate cells did not
appear activated, because there was no increase in midlobular α-SMC staining (data not
shown). Quantitative analysis of the immunostained sections demonstrated that As(III)
increased expression of both PECAM-1 and laminin-1 relative to controls (Fig. 3C). As
reported,35 the increase in PECAM-1 protein expression at the cell junctions did not correlate
with increased PECAM-1 mRNA levels (data not shown).
As(III) Stimulates Vascularization of the PBVP and Hepatic Artery Contraction
The PBVP is often remodeled in alcohol-induced fibrosis and cirrhosis as the hepatic arterial
flow increases to compensate for decreased portal blood flow.18 Arsenic(III) also promoted
vascular remodeling of the PBVP (Fig. 4A-D). Corresponding serial sections were stained with
hematoxylin and eosin (Fig. 4A, C) or co-stained with antibodies to endothelial cell PECAM-1
and α-SMC actin (Fig. 4B, D). The fibrous septal duct wall appeared to thicken and gain
cellularity following As(III) exposure (Fig. 4C compared with 4A). Immunofluorescent
analysis indicated that As(III) caused more pronounced PECAM-1–positive and PECAM/
SMC-positive luminal structures in the septal wall (Fig. 4D versus 4B). Arsenic(III) increased
the number of ductal vessels in the PBVP (Fig. 4E) and decreased hepatic artery luminal
diameter by 3.5-fold (Fig. 4D compared to 4B and graph 4F).
As(III) Increases Caveolin-1 and Membrane Rac1 Protein Expression in SECs
SEC defenestration and capillarization should be associated with functional changes in cell
signaling. Fenestrated endothelium have decreased expression of caveolin-1 and loss or fusion
of caveolae.36,37 To determine whether As(III) reversed suppression of SEC caveolin-1
expression, liver sections were co-immunostained for caveolin-1 and PECAM-1. The confocal
images in Fig. 5A and graph in Fig. 5B con-firmed that caveolin-1 expression in normal
sinusoids is low. Exposure to As(III) increased liver caveolin-1 expression by 5-fold to 6-fold
over control and this increase was localized to PECAM-1 positive sinusoidal cells. This
increase in caveolin-1 staining correlated with the increase in caveolae observed by TEM (Fig.
2). In angiogenesis, Rac1-GTPase regulates endothelial cell cytoskeletal fibers to stabilize the
vessel phenotype with tight cell associations and spreading on a laminin-1 ECM.34 Immuno-
blotting for Rac1 in SEC plasma membranes isolated in situ demonstrated that membrane-
bound GTPase was present in SECs from As(III)-exposed mice (Fig. 6) and not in SEC
membranes from controls. The data in Fig. 6 also demonstrate that chronic As(III) exposure
did not stimulate Rac1 membrane localization in other non-parenchymal cells or hepatocytes.
Discussion
Environmental As(III) exposures increase the incidence of liver diseases, such as noncirrhotic
fibrosis and portal hypertension, in humans.2 These As(III)-associated diseases present with
liver vascular changes including increased vascular channels and arteriovenous shunts.2 While
angiogenesis and SEC maturation appear to play significant roles in disrupting sinusoidal
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vessels,18,22–25 the data presented here are the first to demonstrate that a human-relevant As
(III) exposure induces capillarization and remodels the liver vasculature in vivo. These vascular
phenotypic changes appear to be more sensitive biomarkers for As(III) exposure than As(III)
levels quantified from liver tissue. These As(III)-induced changes in an endogenous vascular
bed are consistent with previous reports that subchronic or chronic exposures to low to
moderate levels of As(III) enhance pathological remodeling in surrogate neovascularization
models and tumors.7,9,28 Decreased SEC porosity and compensatory gain of caveolae
represent potential mechanisms for As(III) to alter liver metabolism and contribute to systemic
vascular diseases. Finally, these data are the first to demonstrate in vivo that As(III) affects
endothelial cell signaling by increasing membrane localization Rac1.
The current data differ significantly from results from previous rodent studies of As(III) effects
on the liver vasculature.2,38–40 The major contrast is that vascular remodeling was observed
following chronic exposure to a moderate As(III) exposure. One previous mouse study
demonstrated that prolonged (9 month) exposure to high-dose As(III) (50–500 μg/mouse/day
by gavage) resulted in liver lipid peroxidation and cytokine release.38 These doses would be
the equivalent of a human drinking 2–20 mg of As(III) perday for approximately 26 years
before inflammatory toxicity occurred. This does not fit the demographic of As(III)-induced
liver disease in humans, because significant increases in urinary porphyrins, a biomarker for
liver injury, are more readily observed in exposed humans who are under 20 years of age.4 In
vivo, high doses of As(III) affect all cells in the liver and promote significant apoptosis in
hepatocytes,40 and doses of As(III) in excess of 5 μM are toxic to endothelial cells.6,8,10,41
It is possible that high-level exposures elicit multiple mechanisms for toxicity that mask
pathogenic mechanisms mediating liver diseases in response to environmentally relevant As
(III) exposures. The current studies used ingestion of drinking water containing a dose of As
(III) that is near the threshold for observing significant liver disease in humans (250 ppb =
~0.7–.9 μg/mouse/day for 5 weeks; human equivalent ~32 μg/day for 3.75 years) to investigate
effects on the vasculature. Thus, the data reflect the effects of As(III) on cell phenotype rather
than cell death.
Capillarization of hepatic sinusoids results in ultra-structural phenotypic conversion to
defenestrated endothelial cells with tight intercellular junctions.16,19,20 In multiple human
and animal studies, capillarization preceded alcohol-induced liver disease, portal hypertension,
cirrhosis, and chronic hepatitis.15,18–20 Arsenic(III) induced SEC PECAM-1 expression and
laminin-1 deposition in the basement membrane (Fig. 3) and correlated directly with decreased
porosity and increased capillarization (Figs. 1 and 2). The data in Fig. 6 confirm that As(III)
stimulated SEC Rac1 membrane mobilization and indicate that this localization was sustained
in SECs during chronic As(III) exposure. Because Rac1 regulates endothelial cell spreading
on laminin-1 matrices during angiogenic vessel maturation,34 it is possible that sustained SEC
Rac1 activation indicates chronic cell signaling changes that support capillarization in response
to As(III) exposure.
Arsenic(III) may stimulate capillarization by disrupting the SEC signaling that maintains
fenestrations and suppresses cell spreading. Tonic stimulation by VEGF promotes fenestrations
and suppresses caveolae in cultured endothelial cells and in a number of vascular beds in
vivo.37,42 In SECs, this maintenance is mediated by stimulated nitric oxide (NO) synthesis.
15 Arsenic(III) inhibits agonist-stimulated NO synthesis in aortic endothelial cells,43 and in
vivo exposure to As(III) limits blood vessel vasoreactivity.44 These inhibitory effects are
mediated by As(III)-stimulated NADPH oxidase generation of super-oxide43 that consumes
NO45 or by decreasing tetrahydrobiopterin levels required for NO synthase activity.44 The
data in Fig. 6 would be consistent with an As(III)-stimulated oxidative state in the SEC, because
Rac1 is an essential component for As(III)-stimulated endothelial cell NADPH oxidase.46–
48 Disrupted VEGF signaling may explain the increase in SEC caveolin-1 expression (Fig. 5).
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37 However, caveolae (Fig. 2) and caveolin-1 (Fig. 5) may have increased to compensate for
the reduced “passive” transendothelial transport because the SEC porosity is significantly
diminished. Increased SEC caveolin-1 would further limit NO generation by sequestering and
inhibiting endothelial NO synthase.49
In summary, these studies are the first to demonstrate that moderate environmental exposure
to As(III) stimulates sinusoidal capillarization and vascular remodeling of the PBVP. These
results are novel in revealing functional remodeling of an endogenous vascular bed in As(III)-
exposed animals. The exposures were not long enough to observe portal fibrosis or changes in
portal blood flow; however, the observed SEC changes were consistent with the pathogenesis
of intrahepatic vascular disease and development of arteriovenous shunts observed in As(III)-
induced human liver diseases.2 Moreover, in vivo exposure of the liver vasculature is a suitable
model for studying arsenic-induced effects that promote both pathogenic vascular cell
responses and liver disease. Further studies using this model will be needed to identify the
molecular switches through which As(III) stimulates phenotypic change in SECs without
promoting hepatocyte injury. These studies will have great impact on the understanding of the
mechanisms for human liver and vascular diseases associated with chronic environmental
exposures to arsenic.
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Arsenic-stimulated capillarization of the liver sinusoidal endothelium. SEM images of
sinusoidal vessels were obtained from thick sections of livers excised from control mice or
mice exposed to 250 ppb As(III) for 5 weeks. In the graph, data are presented as mean ± SD
porosity (open bars = control, closed bars = As(III)-exposed, n = 3), as determined in
experimental procedures. Two-way ANOVA and Bonferroni’s post-test demonstrated no
significant differences between zones, a highly significant effect of arsenic exposure relative
to control (***P < 0.001).
Straub et al. Page 10














Arsenic-stimulated capillarization, basement membrane formation, and increased hepatocyte
microvilli. (A) TEM images of sinusoidal vessels were captured from ultrathin sections of
livers. Representative images are presented with portions magnified (B) to illustrate changes
in the space of Disse and to show increased caveolae (arrows) in As(III)-exposed mice. (Bars
= 500 nm) Abbreviations: SD, space of Disse; L, sinusoid lumen.
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Arsenic(III) induced expression of sinusoidal PECAM-1 and laminin protein. (A) Cryosections
were immunostained for PECAM-1 (green) or laminin-1 (red). Merged images show DRAQ
5 stained nuclei (blue) (bar = 50 μm). (B) Images of portal vein and periportal PECAM-1
(green) and nuclear staining demonstrate PECAM changes in sinusoids, but not in the portal
vein endothelium (L = lumen). (C) Quantitative morphometric analysis of midlobular
PECAM-1 and laminin-1 protein staining is presented as the mean ± SD percentage of total
positive-staining pixels for the respective protein per 400× microscopic field (**P < 0.01 and
*P < 0.05, n = 5 mice).
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As(III) stimulates vascularization of the PBVP and hepatic artery contraction. Serial sections
were prepared from livers from control or As(III)-exposed mice. Sections were stained with
either hematoxylin & eosin [(A) and (C)] or immunostained for PECAM-1 (green) and α-SMC
actin (red) [(B) and (D)]. Final image magnification was 400× (BD = biliary ducts, HA =
hepatic arteries). (E) The mean ± SD of PECAM-positive structures [* in images (B) and (D)]
surrounding at least 2 biliary ducts per section from 5 mice is presented (***P < 0.001). (F)
The luminal areas of hepatic arterioles were calculated. The data are the mean ± SD of the
average luminal areas of at least 2 hepatic arterioles per section from 5 mice in each group.
(**P < 0.01).
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Co-localization of As(III)-stimulated caveolin-1 and PECAM-1 protein expression. Sections
of livers were immunostained for PECAM-1 (green) or caveolin-1 (red). Nuclei were stained
with DRAQ 5 (blue). The white bar = 25 μm. The graph presents mean ± SD percentage of
caveolin-1 positive pixels per 400× microscopic field (**P < 0.01; n = 5).
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Chronic As(III)-stimulated mobilization of Rac1 to SEC luminal membranes. Luminal SEC
membranes of control and As(III) exposed mice were separated from total liver cell membranes
(light fraction), as described in “Materials and Methods”. Rac1 and actin (loading control)
abundance was measured by Western blotting. Each lane presents protein abundance in liver
and SEC membrane fractions from individual mice.
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